IMGN News and Press, ImmunoGen Inc. From 11/30/21

ImmunoGen (NASDAQ:IMGN) soars 32.6% premarket after announcing positive top-line data from the SORAYA trial evaluating the safety and efficacy of mirvetuximab soravtansine (mirvetuximab) monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian ...

Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4% Median Duration of Response at Data Cutoff is 5.9 Months Continued Demonstration of Favorable Tolerability Profile BLA Submission on Track for First Quarter of 2022 Conference Ca...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Kristen Harrington-Smith has been appointed Senior Vice President and Chief Commercial Officer. "We are excited that Kristen has jo...

Bloomberg reports this week that the VIX (the CBOE Volatility Index) is rallying with the S&P 500 in a rare way over the past few weeks. And recent analysis from Susquehanna suggests that this is not because people are bidding up put option contract prices out of valuation jitters but bid...

Triplet Demonstrated Manageable Safety Profile and Encouraging Activity, with 55% Objective Response Rate Across All Doses/Schedules in Escalation Data for IMGN632 in Frontline BPDCN Patients Will Also be Presented ImmunoGen Inc. (Nasdaq: IMGN), a leader in the e...

ImmunoGen released its Q3-2021 earnings and numbers are solid. Positive expectations around SORAYA study. Stock price far from 52-week high. For further details see: ImmunoGen: Strong Catalysts Ahead And Solid Q3 Earnings

Image source: The Motley Fool. ImmunoGen, inc (NASDAQ: IMGN) Q3 2021 Earnings Call Oct 29, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: ImmunoGen, inc (IMGN) Q3 2021 Earnings Call Transcript

ImmunoGen, Inc. (IMGN) Q3 2021 Earnings Conference Call October 29, 2021, 08:00 AM ET Company Participants Courtney O’Konek - Senior Director, Corporate Communications & IR Mark Enyedy - President and CEO Anna Berkenblit - SVP and Chief Medical Officer Susan Altschuller - SVP and C...

ImmunoGen (NASDAQ:IMGN) says it anticipates releasing top-line phase 3 data on its lead candidate, mirvetuximab soravtansine, for platinum-resistant ovarian cancer this quarter, with a BLA submission in Q1 2022. The trial, SORAYA, is evaluating mirvetuximab as monotherapy in a single-arm stud...

ImmunoGen (NASDAQ:IMGN): Q3 GAAP EPS of -$0.18 in-line. Revenue of $9.21M (-49.4% Y/Y) misses by $9.82M. Shares +1.3% PM. Press Release ImmunoGen has updated its financial guidance for 2021 and now expects: Affirms revenue guidance between $65 million and $75 million; operating expenses betwe...